Profile data is unavailable for this security.
About the company
PT Industri Jamu Dan Farmasi Sido Muncul Tbk is an Indonesia-based company, which carries out business activities in herbal industry, such as medical industry (pharmacy), herbs, cosmetics, foods and beverages related to health, commerce, land transportation, services, wastewater treatment, plantation, and printing. The Company's segments include Herbal medicine and supplement, Food and beverages, and Pharmacy. The Company’s products include Tolak Angin Cair, Tolak Angin Anak + Madu, Tolak Angin Flu, Tolak Angin Sugar Free, Sido Muncul Tolak Linu, Kuku Bima Ener-G!, Susu Jahe, Kopi Jahe, Sido Muncul C-1000 (Dengan Ekstrak Lemon), Esemag, Sari Kunyit Soft Capsule, Tolak Angin Soft Capsule, Tolak Linu Soft Capsule, JSH Capsule, VCO Soft Capsule, Sido Muncul Vitamin D3 400 IU, Sido Muncul VItamin E 100 IU, Sido Muncul Vitamin E 300 IU, Minuman Madu dengan Jahe maduSido, Tolak Angin Care, Tolak Linu Cool, Anak Sehat Rasa Anggur, Anak Sehat Rasa Coklat, and Anak Sehat Rasa Jambu Merah.
- Revenue in IDR (TTM)3.65tn
- Net income in IDR1.01tn
- Incorporated1981
- Employees3.60k
- LocationIndustri Jamu dan Farmasi Sido Muncul Tbk PTGedung Menara Suara Merdeka 16th FloorJl. Pandanaran No. 30SEMARANG 50134IndonesiaIDN
- Phone+62 2 476928811
- Fax+62 2 476928815
- Websitehttps://www.sidomuncul.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Shineway Pharmaceutical Group Ltd | 8.58tn | 1.91tn | 14.33tn | 3.22k | 6.87 | 0.8458 | 8.93 | 1.67 | 1.22 | 1.22 | 5.47 | 9.87 | 0.3852 | 1.11 | 4.53 | 1,282,871.00 | 8.57 | 8.29 | 11.40 | 10.38 | 74.95 | 74.83 | 22.24 | 18.67 | 3.18 | -- | 0.0444 | 37.49 | -16.35 | 6.90 | -13.35 | 10.80 | 8.92 | 19.39 |
| Polypeptide Group AG | 6.42tn | -370.89bn | 14.40tn | 1.29k | -- | 2.12 | 65.12 | 2.24 | -0.5527 | -0.5527 | 9.54 | 10.10 | 0.4687 | 2.18 | 4.11 | 244,749.50 | -2.71 | 0.555 | -3.64 | 0.7099 | 11.61 | 19.25 | -5.78 | 1.05 | 0.935 | -0.6831 | 0.227 | 62.37 | 4.28 | 10.70 | 61.97 | -- | 34.57 | -- |
| Jiangsu Jibeier Pharmaceutical Co Ltd | 2.05tn | 490.99bn | 14.62tn | 1.33k | 29.14 | 2.80 | -- | 7.12 | 1.11 | 1.11 | 4.60 | 11.52 | 0.3797 | 3.35 | 3.90 | 681,314.40 | 9.07 | 8.99 | 9.74 | 9.78 | 87.92 | 88.72 | 23.89 | 23.97 | 8.07 | -- | 0.0102 | 32.97 | 4.14 | 10.57 | 0.1095 | 14.20 | 42.01 | -- |
| Jiangsu Aidea Pharmaceutical Co Ltd | 1.19tn | -254.22bn | 15.08tn | 704.00 | -- | 6.67 | -- | 12.71 | -0.2662 | -0.2662 | 1.24 | 2.37 | 0.2866 | 0.9355 | 3.09 | 742,572.90 | -5.46 | -4.33 | -8.57 | -5.36 | 58.53 | 40.16 | -19.06 | -20.35 | 0.9916 | -- | 0.32 | -- | 1.57 | 3.89 | -85.63 | -- | 5.88 | -- |
| Industri Jamu dn Frms Sd Mncl Tbk PT | 3.65tn | 1.01tn | 15.15tn | 3.60k | 14.95 | 4.08 | 13.45 | 4.15 | 33.79 | 33.79 | 121.84 | 123.72 | 0.8753 | 3.56 | 4.59 | 1,025,467,000.00 | 24.27 | 27.62 | 26.72 | 31.69 | 57.14 | 56.70 | 27.73 | 28.98 | 5.45 | -- | 0.0009 | 97.08 | 9.90 | 5.02 | 23.18 | 7.71 | -19.12 | 9.91 |
| Tchaikapharma High Quality Medicines AD | 544.45bn | 50.36bn | 15.27tn | 207.00 | 397.83 | 14.09 | 195.13 | 28.04 | 0.0431 | 0.0431 | 0.1569 | 1.22 | 0.4398 | 2.50 | 0.8677 | 271,009.70 | 4.07 | 2.11 | 4.67 | 2.44 | 33.35 | 29.47 | 9.25 | 5.56 | 4.06 | 38.39 | 0.0892 | -- | 9.72 | 8.94 | 32.14 | 11.82 | -- | -- |
| F D C Ltd | 3.99tn | 504.47bn | 15.36tn | 6.66k | 30.41 | 3.56 | 25.34 | 3.85 | 16.40 | 16.40 | 129.65 | 140.11 | 0.8137 | 1.93 | 18.64 | -- | 10.30 | 11.35 | 11.83 | 12.96 | 65.07 | 61.95 | 12.66 | 14.75 | 1.97 | 58.47 | 0.0092 | -- | 8.50 | 9.42 | -12.59 | 2.15 | 25.37 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Jul 2025 | 221.03m | 0.74% |
| eQ Varainhoito Oyas of 31 Jan 2024 | 209.15m | 0.70% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 118.78m | 0.40% |
| First Sentier Investors (UK) IM Ltd.as of 30 Apr 2025 | 108.08m | 0.36% |
| Mellon Investments Corp.as of 03 Jul 2025 | 98.74m | 0.33% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 80.11m | 0.27% |
| Templeton Investment Counsel LLCas of 30 May 2025 | 77.31m | 0.26% |
| TIAA-CREF Investment Management LLCas of 30 Apr 2025 | 63.68m | 0.21% |
| AllianceBernstein Ltd.as of 31 Mar 2025 | 53.84m | 0.18% |
| Franklin Templeton Investments (Asia) Ltd.as of 30 Sep 2024 | 41.05m | 0.14% |
